Desensitization of insulin secretion by depolarizing insulin secretagogues

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Rustenbeck, Ingo ^a   Wienbergen, Antje ^a   Bleck, Claudia ^a   Jörns, Anne ^b  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ION; IMIDAZOLINE; INSULIN; POTASSIUM CHANNEL; QUININE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ANIMAL CELL; APOPTOSIS; BIOGENESIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CELL ULTRASTRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DESENSITIZATION; EXOCYTOSIS; IMMUNOREACTIVITY; IN VITRO STUDY; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SECRETORY GRANULE;

ANIMALS; BENZOFURANS; CALCIUM; HUMANS; IDAZOXAN; IMIDAZOLES; INSULIN; ISLETS OF LANGERHANS; MEMBRANE POTENTIALS; POTASSIUM CHANNELS;

EID: 9444242168     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S140     Document Type: Conference Paper

References (79)

1. Rosetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
2. Robertson RP, Olson LK, Zhang HJ: Differentiating glucose toxicity from glucose desensitization: a new message form the insulin gene. Diabetes 43:1085-1089, 1994
3. Klöppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125, 1985
4. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A: β-cell adaption and decompensation during the progression of diabetes. Diabetes 50: S154-S159, 2001
5. Groop L, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D: Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9:129-133, 1986
6. Robertson RP: Defective insulin secretion in NIDDM: integral part of a multiplier hypothesis. J Cell Biochem 48:227-233, 1992
7. Rustenbeck I: Desensitization of insulin secretion. Biochem Pharmacol 63:1921-1935, 2002
8. Grill V, Westberg M, Östenson CG: B-cell insensitivity in a rat model of non-insulin-dependent diabetes: evidence for a rapidly reversible effect of previous hyperglycemia. J Clin Invest 80:664-669, 1987
9. Anello M, Rabuazzo AM, Degano C, Caltabiano V, Patanè G, Vigneri R, Purrello F: Fast reversibility of glucose-induced desensitization in rat pancreatic islets. Diabetes 45:502-506, 1996
10. Kaiser N, Corcos AP, Sarel I, Cerasi E: Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology 129:2067-2076, 1991
11. Davalli AM, Pontiroli A, Socci C, Bertuzzi F, Fattor B, Braghi S, DiCarlo V, Pozza G: Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than β-cell exhaustion. J Clin Endocrinol Metab 74:790-794, 1992
12. Bedoya FJ, Jeanrenaud B: Insulin secretory response to secretagogues by perifused islets from chronically glucose-infused rats. Diabetes 40:15-19, 1991
13. Robertson RP: Type II diabetes, glucose "non-sense", and islet desensitization. Diabetes 38:1501-1505, 1989
14. Leahy JL: β-cell dysfunction with chronic hyperglycemia: the "overworked β-cell" hypothesis. Diabetes Rev 4:298-319, 1996
15. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D: Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48:1230-1236, 1999
16. Ling Z, Kiekens R, Mahler T, Schult F, Pipeleers-Marichal M, Sener A, Klöppel G, Malaisse WJ, Pipeleers DG: Effects of chronically elevated glucose levels on the functional properties of rat pancreatic β-cells. Diabetes 45:1774-1782, 1996
17. Andersson A, Westmann J, Hellerström C: Effects of glucose on the ultrastructure and insulin biosynthesis of isolated mouse pancreatic islets maintained in tissue culture. Diabetologia 10:743-753, 1974
18. Grodsky GM: A new phase of insulin secretion: how will it contribute to our understanding of β-cell function? Diabetes 38:673-678, 1989
19. Grill V, Björklund A: Overstimulation and β-cell function. Diabetes 50: S122-S124, 2001
20. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H: Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581-587, 2003
21. Ashcroft FM, Rorsman P: Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 54:87-142, 1991
22. Barg S: Mechanism of exocytosis in insulin-secreting B-cells and glucagon-secreting A-cells. Pharmacol Toxicol 92:3-13, 2003
23. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351, 1998
24. Schulz A, Hasselblatt A: An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-receptors. Naunyn-Schmiedeberg's Arch Pharmacol 340:712-714, 1989
25. Chan SLF, Morgan NG: Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Br J Pharmacol 176:97-101, 1990
26. Rustenbeck I, Leupolt L, Kowalewski R, Hasselblatt A: Heterogeneous characteristics of imidazolines-induced insulin secretion. Naunyn-Schmiedeberg's Arch Pharmacol 359:235-242, 1999
27. + channels in pancreatic β-cells. Br J Pharmacol 107:8-14, 1992
28. ATP channels is mediated by Kir6.2. Proc Natl Acad Sci U S A 94:11716-11720, 1997
29. ATP channels and interaction with the exocytotic machinery. Diabetes 45:1610-1618, 1996
30. Mourtada M, Chan SLF, Smith SA, Morgan NG: Multiple effector mechanisms regulate the insulin secretory response to the imidazoline RX-871024 in isolated rat pancreatic islets. Br J Pharmacol 127:1279-1287, 1999
31. Rustenbeck I, Köpp M, Polzin C, Hasselblatt A: No evidence for PKC activation in stimulation of insulin secretion by phentolamine. Naunyn-Schmiedeberg's Arch Pharmacol 358:390-393, 1998
32. ATP channel activity. Diabetes 50:797-802, 2001
33. Efendic S, Efanov A, Berggren PO, Zaitsev A: Two generations of insulinotropic imidazoline compounds (Abstract). Diabetes 51 (Suppl. 2):S448-S454, 2002
34. 2+-dependent exocytosis in pancreatic α- and β-cells. Eur J Pharmacol 446:213-221, 2003
35. Smith PA, Sakura H, Coles B, Gummerson N, Proks P, Ashcroft FM: Electrogenic arginine transport mediates stimulus-secretion-coupling in mouse pancreatic β-cells. J Physiol 499:625-635, 1997
36. Dunbar JC, Foa PP: An inhibitory effect of tolbutamide and glibenclamide on the pancreatic islets of normal animals. Diabetologia 10:27-32, 1974
37. Filliponi P, Marcelli M, Nicoletti I, Pacifici R, Santeusanio F, Brunetti P: Suppressive effect of long-term sulfonylurea treatment on A, B, and D cells of normal rat pancreas. Endocrinology 113:1972-1979, 1983
38. Karam JH, Sanz E, Salomon E, Nolte MS: Selective unresponsiveness of pancreatic B-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 35:1314-1320, 1986
39. Zawalich WS: Phosphoinositide hydrolysis and insulin secretion in response to glucose are impaired in isolated rat islets by prolonged exposure to the sulfonylurea tolbutamide. Endocrinology 125:281-286, 1989
40. Gullo D, Rabuazzo AM, Vetri M, Gatta C, Vinci C, Buscema M, Vigneri R, Purrello F: Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets. J Endocrinol Invest 14:287-291, 1991
41. Rabuazzo AM, Buscema M, Vinci C, Caltabiano V, Vetri M, Forte F, Vigneri R, Purello F: Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology 131:1815-1820, 1992
42. Henquin JC: Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia 18:151-160, 1980
43. Hu S, Wang S, Dunning BE: Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas. Int J Exp Diabetes Res 2:73-79, 2001
44. Rustenbeck I, Dickel C, Grimmsmann T: Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. II. Electrophysiological and fluorimetric studies. Biochem Pharmacol 62:1695-1703, 2001
45. + channel activity. Diabetes 48:2001-2006, 1999
46. Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S: Control of insulin secretion by sulfonylureas, meglitinide, and diazoxide in relation to their binding to the sulfonyurea receptor in pancreatic islets. Biochem Pharmacol 38:1217-1229, 1989
47. 2+ regulation prevail over changes in insulin content. Br J Pharmacol 127:1883-1891, 1999
48. Schauder P, Arends J, Frerichs H: Onset and reversibility of changes in secretory function and composition of isolated rat pancreatic islets following long-term administration of high or low tolbutamide doses. Metabolism 26:9-15, 1977
49. McClenaghan N, Ball AJ, Flatt P: Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide. Br J Pharmacol 130:478-484, 2000
50. Rustenbeck I, Winkler M, Jörns A: Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. I. Secretory and morphological studies. Biochem Pharmacol 62:1685-1694, 2001
51. Williamson JR, Lacy PE, Grisham JW: Ultrastructural changes in islets of the rat produced by tolbutamide. Diabetes 10:460-469, 1961
52. Lee JC, Grodsky GM, Bennett LL, Smyth-Kyle DF, Craw L: Ultrastructure of β-cells during the dynamic response to glucose and tolbutamide in vitro. Diabetologia 6:542-549, 1970
53. Engelbart K, Bähr H, Kief H: Ultrastruktur der B-Zellen des Rattenpankreas nach ein- und mehrmaliger Gabe von HB419. Drug Res 19:1456-1463, 1969
54. Bänder A, Pfaff W, Schesmer G: Lichtoptisch-morphologische Untersuchungen an der B-Zelle der Langerhans'schen Insel nach Verabreichung von HB419. Drug Res 19:1448-1451, 1969
55. Pfaff W, Schöne HH: Zur Insulinfreisetzung aus Pankreas durch Sulfonylharnstoffe. Drug Res 19:1445-1448, 1969
56. Hakan Borg L, Andersson A: Long-term effects of glibenclamide on the insulin production, oxidative metabolism, and quantitative ultrastructure of mouse pancreatic islets maintained at different glucose concentrations. Acta Diabetol Lat 18:65-83, 1981
57. Loubatieres A: Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides. Acta Diabetol Lat 6 (Suppl. 1):216-255, 1969
58. Schauder P, Frerichs H: Tolbutamide-induced changes of the DNA, protein and insulin content and the secretory activity of isolated rat pancreatic islets. Diabetologia 11:301-305, 1975
59. Hellman B, Idahl LA, Danielsson A: Adenosine triphosphate levels of mammalian pancreatic B-cells after stimulation with glucose and hypoglycemic sulfonylureas. Diabetes 18:509-516, 1969
60. Ashcroft SJH, Weerasinghe LC, Randle PJ: Interrelationsship of islet metabolism, adenosine triphosphate content and insulin release. Biochem J 132:223-231, 1973
61. Panten U, Zünkler BJ, Scheit S, Kirchhoff K, Lenzen S: Regulation of energy metabolism in pancreatic islets by glucose and tolbutamide. Diabetologia 29:648-654, 1986
62. Morgan NG, Chan SLF: Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharmaceut Design 7:1413-1431, 2001
63. 2 sites. Br J Pharmacol 112:1065-1070, 1994
64. ATP channels in insulin-secreting cells. Eur J Pharmacol 204:41-48, 1991
65. + channel-blocking compounds. Diabetes 53 (Suppl. 3):S135-S139, 2004
66. Ball AJ, McCluskey J, Flatt P, McClenaghan N: Drug-induced desensitization of insulinotropic actions of sulfonylureas. Biochem Biophys Res Commun 271:234-239, 2000
67. Chapman JC, McClenaghan NH, Cosgrove K, Hashmi N, Sheperd R, Giesberts A, White S, Δmmälä C, Flatt P, Dunne MJ: ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN BD11 β-cell line. Diabetes 48:2349-2357, 1999
68. Gold G, Pou J, Gishizky L, Landahl HD, Grodsky GM: Effects of tolbutamide pretreatment on the rate of conversion of newly synthesized proinsulin to insulin and the compartmental characteristics of insulin storage in isolated islets. Diabetes 35:6-12, 1986
69. Hosokawa YA, Leahy JL: Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes 46:808-813, 1997
70. 2+ concentration. J Biol Chem 273:33501-33507, 1998
71. Mourtada M, Elliott J, Smith SA, Morgan NG: Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic β-cells. Naunyn-Schmiedeberg's Arch Pharmacol 361:146-154, 2000
72. + channel-blocking insulin secretagogues. Biochem Pharmacol 67:1733-1741, 2004
73. Arvan P, Halban PA: Sorting ourselves out: seeking consensus on trafficking in the beta-cell. Traffic 5:53-61, 2004
74. Gold G, Gishizky ML, Grodsky GM: Evidence that glucose "marks" β-cells resulting in preferential release of newly synthesized insulin. Science 218:56-58, 1982
75. Duncan RR, Greaves J, Wiegand UK, Matskevich I, Bodammer G, Apps DK, Shipston MJ, Chow RH: Functional and spatial segregation of secretory vesicle pools according to vesicle age. Nature 13:176-180, 2003
76. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760, 2000
77. Detimary P, Gilon P, Nenquin M, Henquin JC: Two sites of glucose control of insulin release with distinct dependence on the energy state in pancreatic B-cells. Biochem J 297:455-461, 1994
78. Rustenbeck I, Herrmann C, Grimmsmann T: Energetic requirement of insulin secretion distal to calcium influx. Diabetes 46:1305-1311, 1997
79. 2+-dependent exocytosis in pancreatic B-cells. Proc Natl Acad Sci U S A 96:760-765, 1999